An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
Public ClinicalTrials.gov record NCT03308968. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in participants with chronic migraine (CM) or episodic migraine (EM) who have responded inadequately to 2 to 4 classes of prior preventive treatments. Approximately equal numbers of participants from each subgroup (CM and EM) are randomized in blinded-fashion 1:1:1 into one of 3 treatments for the subgroup - 2 active treatments and 1 placebo treatment- consisting of monthly injections for 3 months (up to Week 12). Then all participants continue into an open-label extension of 3 months (up to Week 24) during which everyone is administered sc injections of fremanezumab.
Study identification
- NCT ID
- NCT03308968
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 838 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2017
- Primary completion
- Oct 1, 2018
- Completion
- May 28, 2019
- Last update posted
- Nov 8, 2021
2017 – 2019
United States locations
- U.S. sites
- 30
- U.S. states
- 21
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 14742 | Huntsville | Alabama | 35801 | — |
| Teva Investigational Site 14729 | Long Beach | California | 90806 | — |
| Teva Investigational Site 14739 | San Diego | California | 92103 | — |
| Teva Investigational Site 14843 | Santa Monica | California | 90404 | — |
| Teva Investigational Site 14749 | Colorado Springs | Colorado | 80918 | — |
| Teva Investigational Site 14758 | Maitland | Florida | 32751 | — |
| Teva Investigational Site 14738 | Orlando | Florida | 32819 | — |
| Teva Investigational Site 14760 | Decatur | Georgia | 30030 | — |
| Teva Investigational Site 14737 | Meridian | Idaho | 83642 | — |
| Teva Investigational Site 14730 | Chicago | Illinois | 60607 | — |
| Teva Investigational Site 14740 | Evanston | Illinois | 60201 | — |
| Teva Investigational Site 14735 | Louisville | Kentucky | 40223 | — |
| Teva Investigational Site 14747 | Pikesville | Maryland | 21208 | — |
| Teva Investigational Site 14750 | Fall River | Massachusetts | 02720 | — |
| Teva Investigational Site 14734 | Watertown | Massachusetts | 02472 | — |
| Teva Investigational Site 14731 | Ann Arbor | Michigan | 48104 | — |
| Teva Investigational Site 14748 | Plymouth | Minnesota | 55441 | — |
| Teva Investigational Site 14746 | Omaha | Nebraska | 68114 | — |
| Teva Investigational Site 14754 | Berlin | New Jersey | 08009 | — |
| Teva Investigational Site 14752 | Albuquerque | New Mexico | 87102 | — |
| Teva Investigational Site 14753 | Amherst | New York | 14226 | — |
| Teva Investigational Site 14736 | Greensboro | North Carolina | 27405 | — |
| Teva Investigational Site 14741 | Greensboro | North Carolina | 27408 | — |
| Teva Investigational Site 14732 | Raleigh | North Carolina | 27607 | — |
| Teva Investigational Site 14761 | Lincoln | Rhode Island | 02865 | — |
| Teva Investigational Site 14756 | Warwick | Rhode Island | 02886 | — |
| Teva Investigational Site 14745 | Memphis | Tennessee | 38119 | — |
| Teva Investigational Site 14743 | Nashville | Tennessee | 37203 | — |
| Teva Investigational Site 14733 | Austin | Texas | 78731 | — |
| Teva Investigational Site 14751 | West Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03308968, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2021 · Synced Sep 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03308968 live on ClinicalTrials.gov.